BIO-TECHNE Corp (TECH) · Nov 3, 2026 · Other events

Bio-Techne dividend stays at $0.08 as Merck deal nears

Dividend declared — $0.08 per share, unchanged from the prior quarter

Bio-Techne’s latest dividend keeps the quarterly payout at $0.08, with payment conditional on whether Merck’s acquisition closes before the record date.

Bio-Techne is a roughly $1.2 billion life-sciences tools company transitioning from standalone operations to an expected Merck KGaA acquisition; shareholders approved the deal in September, while closing remains targeted for late 2026 or early 2027, subject to remaining conditions.

The filing confirms a routine quarterly payout, not a new capital-allocation signal. Bio-Techne declared $0.08 per share for the quarter ended September 30, payable November 23 to holders of record November 13, provided the Merck transaction has not closed by then. The amount matches the prior quarterly dividend, so this is continuity rather than an increase or cut.

CurrentPrior quarter
Quarterly dividend (Exhibit 99.1)$0.08/share$0.08/share

The only incremental detail is the closing-date condition. The dividend will not be paid under this schedule if Merck completes the acquisition on or before November 13, making the transaction timeline the operative issue rather than the dividend itself. 〔0〕

Bottom line: This is housekeeping during the pending Merck sale: the dividend is unchanged and the business story is unaffected. The meaningful next event is deal completion, not the payout declaration.

What to watch next

Merck transaction closing, late 2026 or early 2027

Original filing on SEC EDGAR

More BIO-TECHNE Corp news

Bio-Techne dividend stays at $0.08 as Merck deal nears | TECH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.